WHO To Assess Impact Of Biological Qualifier Scheme
This article was originally published in SRA
Executive Summary
The World Health Organization is looking for an outside body to assess the expected impact of its planned 'biological qualifier' for biological medicines (BQ) on stakeholders because of the many divergent opinions that have been expressed over the proposal, which was finalized last year and has now been published1,2.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.